Condition
Post-Viral Fatigue Syndrome
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 1 (1)
P 2 (2)
Trial Status
Completed3
Unknown1
Suspended1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07454395Not ApplicableSuspended
Is Swimming a More Tolerable Form of Movement for Individuals With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome?
NCT05430152Phase 2CompletedPrimary
Low-dose Naltrexone for Post-COVID Fatigue Syndrome
NCT04705831Phase 2CompletedPrimary
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
NCT05664711Phase 1Completed
Effect of Stellate Ganglion Block on ME/CFS
NCT05130736Not ApplicableUnknownPrimary
Rehabilitation Robot in Patients With Post-Coronavirus Disease (COVID-19) Fatigue Syndrome
Showing all 5 trials